Antev Ltd., a late clinical-stage biotech company developing a novel gonadotrophin-releasing hormone antagonist, Teverelix trifluoroacetate, announces that the US Food & Drug Administration has provided written guidance on the company’s proposed Phase 3 pivotal trial design.
